QTREX Quantum Ltd. shares have closed above the $1.00 minimum bid price for six consecutive business days, a development that precedes the company's deadline to formally demonstrate compliance with Nasdaq listing requirements. The stock, which trades on The Nasdaq Capital Market under the symbol QTEX, remained listed and tradable despite a written notification received from the exchange regarding a prior period of non-compliance.
On October 5, 2026, the Listing Qualifications Department of The Nasdaq Stock Market LLC informed QTREX that its ordinary shares fell below the $1.00 threshold required by Nasdaq Listing Rule 5550(a)(2). The notification covered the 30 consecutive business days from August 20, 2026, through October 1, 2026. The company stated that this notification carries no immediate effect on the listing or trading of its shares.
Since the end of that measurement period, the closing bid price of QTREX ordinary shares has exceeded $1.00 on each of the six business days from October 2, 2026, through October 9, 2026. Under Nasdaq Listing Rule 5810(c)(3)(A), the company is granted a period of 180 calendar days from the date of the notification to regain full compliance. This period expires on April 3, 2027.
To close the matter and receive written confirmation of compliance from Nasdaq, QTREX must maintain a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days at any time during the 180-day window. The company has not yet received this final confirmation, though current trading levels suggest progress toward that specific benchmark.
QTREX Quantum Ltd., based in Ness Ziona, Israel, specializes in electronics manufacturing and connectivity systems designed for quantum computers and other high-performance hardware sectors. After securing its Additively Manufactured Electronics (AME) platform, the firm is working on dense, thermally efficient connections for dilution cryostats. It is also expanding AME uses in defense, aerospace, missile, and space sectors while continuing to develop its medical technology portfolio, which includes respiratory support and blood monitoring platforms.
The company's press release includes forward-looking statements regarding its anticipated share performance and efforts to regain compliance with Nasdaq regulations. These statements are based on current management expectations and are subject to uncertainties that could cause actual results to differ materially. Further details on risks are contained in the company's annual report on Form 20-F for the fiscal year ended December 31, 2025.